MAPT and Alzheimer disease: The principal validated biomarkers for AD rely heavily on molecular changes in the known amyloid/Tau pathology of AD, represented by decreased β-amyloid and increased Tau in cerebrospinal fluid (CSF) [8–10], and/or increased brain amyloid or Tau by positron emission tomography (PET) [11].